Glioblastomas, the most common and aggressive form of astrocytoma, are refractory to therapy, and molecularly heterogeneous. The ability to establish cell cultures that preserve the genomic profile of the parental tumors, for use in patient specific in vitro and in vivo models, has the potential to revolutionize the preclinical development of new treatments for glioblastoma tailored to the molecular characteristics of each tumor.
Introduction
Glioblastoma (GBM), a WHO grade IV astrocytoma, is the most prevalent and aggressive primary brain tumor. Diverse developmental phenotypes are adopted by GBM tumor cells, including cells exhibiting "cancer stem cell" (CSC) characteristics, such as the expression of neural stem cell (NSC) markers, long term self-renewal, and the potential to give rise to more differentiated cells expressing astrocytic markers and forming the bulk of the tumor [1] [2] [3] . While clarification is still needed regarding CSC molecular identity and clinical implications, the focus of the present work is on the operational definition of CSC: long term self-renewal in vitro and the ability to differentiate and reproduce the original tumor upon orthotopic implantation in immunocompromised rodents.
Glioblastoma cells have been cultured for decades in traditional medium containing 10% fetal bovine serum (FBS) and several high passage commercially available serum cultured GBM cell lines are tumorigenic in immunocompromised rodents, but there is considerable genomic and molecular divergence from the original tumor 4 , limiting their use as clinically relevant models. More recently, cells with stem/progenitor phenotype responsive to EGF and bFGF were identified in GBMs 2 . Subsequently, dissociated GBM tumor samples were cultured in a serum-free medium 3 , originally formulated for the selection and expansion of neural stem cells from the adult mammalian brain 5 . These culture conditions hinder the growth of most nonneoplastic and more differentiated tumor cell populations, while favoring the growth of stem and progenitor cells as floating multicellular spheroids, or neurospheres 3 , mimicking the behavior of adult mammalian neural stem cells 5 . Comprehensive side by side comparison of primary GBM cells cultured in either neurosphere medium supplemented with growth factors (NMGF) or in the traditional growth medium supplemented with 10% FBS, revealed that the GBM neurospheres were tumorigenic, presented multilineage differentiation potential, and preserved the genotype of the original tumor, in contrast to the 10% FBS cultures which were not tumorigenic at low passages and considerably diverged from the original tumors at late passages 4 .
Isolation of CSC from dissociated GBM tumors by cell sorting based on the expression of putative CSC marker CD133 has also been proposed 6, 7 , but further work indicated that the CSC phenotype is not definitively associated with the expression of such markers [8] [9] [10] , decreasing the initial enthusiasm for this strategy, whereas new markers are still being tested routine CSC-enriched cultures. GBM cells selected by the ability to grow as neurospheres in NMGF invariably express neural stem cell markers. We have observed that Sox2 and nestin are ubiquitously expressed in neurosphere cultures, while CD133 protein is present in a subset of the GBM neurospheres (unpublished data and reference 11 ).
Several laboratories are pursuing neurosphere cultures from glioblastoma tumors using the same general approach of enzymatic dissociation and culturing in serum-free medium supplemented with growth factors 3, 4, [11] [12] [13] [14] , while other colleagues have reported attempts to grow long term neurosphere cultures from GBM samples without success . The general method for enzymatic dissociation and neurosphere culture of high grade gliomas presented here is similar to what has been outlined in the above publications. We have optimized the protocol based on our experience of dissociating and culturing over 100 GBM samples. The efficiency of obtaining long-term neurosphere cultures from fresh GBM samples applying the protocol presented here is over 40%, similar to the few reports showing efficiency data 3, 15 , leading to the exploration of alternative protocols such as culturing cells continually or intermittently in serum-free medium in the presence of EGF and bFGF as monolayers on surfaces coated with ECM protein 16, 17 . Neurosphere cultures are still the most validated and increasingly popular approach to preserve GBM tumors molecular characteristics and tumorigenic potential 3, 4, [11] [12] [13] [14] , thus our approach is to attempt neurospheres cultures first, while concomitantly testing alternative methods for culturing GBM cells that fail to form long term self-renewing neurospheres (Figure 1) , to increase the representation of GBM tumors that can be used in animal models. Here we present a protocol for culturing neurospheres from GBMs. For cells that fail to form neurospheres, we show a simple modification in the growth medium, as the first attempt to culture tumorigenic cells from nonneurosphere forming GBMs, with promising results and still undergoing extensive validation.
Protocol

Single Cell Suspension from Fresh Surgical Glioblastoma Specimen for Neurosphere Culture
1. With written consent from patients and in accordance with institutional guidelines, collect tumor samples for cell culture immediately after resection surgery of high grade glioma. 2. Confirm diagnosis of tumor sample by histopathology. Immediately transport the specimen from the operation room to the laminar flow tissue culture hood, for processing within 1 hr from surgery. NOTE: For surgeries at a remote site, cut the tumor sample into smaller fragments and place into a tube containing DMEM/F12 (keep on ice). The tumor can be processed several hours after surgery. 3. Starting with 200-500 mg of tissue (optimal), mince the tumor sample using a scalpel blade, and transfer to a 15 ml tube containing 10 ml DMEM/F12 serum-free medium. Mix by inverting several times, let the tumor pieces sediment by gravity, remove medium, and repeat as necessary. 4. Prepare the Enzymatic Tissue Dissociation Solution and Stop Solution fresh.
1. Enzymatic Tissue Dissociation Solution: 5 ml 0.05% Trypsin-EDTA, 2.5 ml Hank's Balanced Salt Solution (HBSS) calcium-and magnesium-free, 2.5 ml Collagenase IV stock solution (2,000 U/ml in HBSS with calcium and magnesium). 2. Stop Solution: 5 ml Trypsin Inhibitor solution, 5 ml DMEM/F12, 2 μl of 5,000 U/ml DNAse I (made in HBSS calcium-and magnesiumfree).
5. Remove medium and add Enzymatic Tissue Dissociation Solution to the minced tumor sample, using 2 ml for each 0.5 g tissue. Gently mix by inverting. 6. Incubate the tissue in solution at 37 °C in a tissue culture incubator under rotation for 30 min. 7. Triturate with a 2 ml pipette and stop the digestion or return to the incubator for another 15-30 min incubation depending on the level of digestion. 8. Stop digestion by adding 2 volumes of Stop Solution and triturate mechanically with a 5 ml serological pipette. 9. Filter out the undigested material through a 40 μm cell strainer. Pellet the cells at 800 x g for 5 min at room temp, followed by washing 3x in 10 ml DMEM/F12. 10. Resuspend the final cell pellet in 5 ml DMEM/F12. 11. Slowly layer the cell suspension over 5 ml of Lympholyte-M and pellet at 1,300 x g for 20 min at room temperature. 12. Transfer the interface layer containing the nucleated cells to a 15 ml tube containing 10 ml of DMEM/F12. 13. Pellet the cells at 800 x g for 5 min at room temperature. Repeat the wash with DMEM/F12 2x more. 14. Cryopreserve the resulting single cells for further use by resuspending the pellet in Recovery Cell Freezing Medium, aliquoting into cryovials, slow freezing, and storing in liquid nitrogen. 15. To culture, resuspend the cells in Neurosphere Medium supplemented with Growth Factors (NMGF), and plate at relatively low density (<1 x 10 5 cells/ml) in a regular T25 tissue culture flask under standard conditions, 5% CO 2 , 37 °C, humidified tissue culture incubator ( Figure 1A ).
1. Prepare NMGF using the following recipe 250 mg/ml BSA stock solution 1 ml 0.5 mg/ml 10 mg/ml Gentamicin reagent 1.25 ml 25 μg/ml 100x antibiotic/antimycotic 2.5 ml 0.5x 100 mg/ml bFGF 0.1 ml 20 ng/ml
Representative Results
We have applied the protocol described above to dissociate and culture 125 fresh surgical glioblastoma specimens (Figure 1) , 88 newly diagnosed, and 37 recurrent tumors ( Table 2) , with approved patient consent and under institutional guidelines. The efficiency of the protocol for establishing long term neurosphere cultures was 41.6%, and similar for newly diagnosed tumors and recurrent tumors ( Table 2) . For some GBM samples, neurospheres form in the first few days (Figures 1B and 1C) , while for others longer culturing time is required (Figures 1D and 1E) .
Efficiency of neurosphere formation was not exclusively dependent on the level of necrosis in the tissue, as exemplified by the results from a newly diagnosed tumor with high cell density (GBM1) and a recurrent and necrotic tumor (GBM2) processed according to Protocols 1 and 2, both yielding neurosphere cultures (Figure 2) .
Testing the tumorigenic potential of each neurosphere culture in immunocompromised mice is the crucial validation of this approach for enrichment of CSCs. Using a protocol similar to previously described 18 , GBM1 and GBM2 neurospheres were implanted into the brains of immunocompromised mice, under institutional and IACUC animal care guidelines. The xenograft tumors present morphological characteristics of GBMs, such as invasion into the brain parenchyma and necrosis (Figure 2) . Figure 1A ) and cultured in neurosphere medium (Figures 1D and 1E) , and in 2% FBS/NMGF (Figures 1D, 1G , and 1H). Monolayer cells cultured in 2% FBS/NMGF and neurosphere cells cultured in NMGF were dissociated and the same number of cells were implanted in nude mouse, using the same procedure as in Figure 2 . No differences in survival, tumor growth dynamics, or morphology were observed between the two preimplant culture methods (Figures 3A-C) . Tumor growth characteristics do not change up to the latest passage tested, P20 for neurospheres, and P10 for 2% FBS/NMGF. While neural stem cell markers, including Sox2, are downregulated in most primary GBM cells cultured in 10% FBS 3, 4, 11 , NMGF supplemented with 2% FBS allows for the retention of Sox2 expression ( Figure 3D ).
GBM3 was dissociated (
Neurospheres were processed according to Protocol 4, and labeled with H&E ( Figure 4A) , anti-Sox2 antibody, showing nuclear localization (Figure 4B) , and EGFR antibody, cell membrane localization ( Figure 4C ). This protocol has been applied to access stimuli-dependent alterations in the expression of nestin, GFAP, and the proliferation marker Ki67 
Discussion
Proper enzymatic tumor cell dissociation is a critical step in this protocol. The tissue must be minced well prior to incubation in cell dissociation solution at 37 °C under rotation, for a minimum of 30 min, when the tissue must be mechanically triturated and the extension of the dissociation verified. Depending on the degree of tissue cohesion, incubation can be extended for additional 15-30 min, as needed to complete dissociation into single cells. Incubation in dissociation solution for longer than 1 hr is not recommended due to decreased cell viability. Although the optimal amount of starting tissue is 200-500 mg, this protocol has led to successful neurosphere cultures from as little as 50 mg of tumor tissue.
Serum-free NMGF is a selective medium, and a percentage of neoplastic cells comprising the bulk of the tumor, as well as host cells, will not survive, while others will attach to the tissue culture treated flask after plating. It is critical that the neurospheres that will form over 1-3 weeks (Figures 1B-E) are transferred to fresh flasks, to separate from differentiated tumor cells and debris. 19, 20 . In addition to being vital for generating patient-specific GBM animal models, the neurosphere cultures are also valuable for in vitro studies such as alteration in cell signaling and gene expression in response to growth factors, hypoxia, and pharmacological agents 11, 21 . We have opted for using cross-sections of formalin fixed and paraffin embedded neurospheres, preserving the 3D architecture, to study protein expression and post-translational modifications by immunohistochemistry 11 , due to the superior subcellular localization in relation to the more common method of labeling and imaging the whole sphere.
It has been shown that not all cells within neurospheres derived from adult mammalian brain are stem cells 22 . Similarly, the neurospheres cultured from GBM tumors are likely not clonal, due to the presence of more differentiated cancer progenitor cells and self-aggregation, known to occur at high cell densities 23 , which is considered a limitation of this method by some. To favor enrichment for long term self-renewing stem cells, as opposed to just progenitors which can transiently grow as neurospheres 22 , the primary neurospheres are dissociated for secondary neurosphere formation, and further passaged for a minimum of 10 passages, roughly equivalent to 2 months in continuous culture, which is an indication of a population enriched in stem cells 22 . In our experience, GBM neurosphere cultures that achieve that mark can continue to be expanded as neurospheres indefinitely. Tumor grade matters, since we have obtained successful cultures from GBMs and anaplastic astrocytomas, WHO grade IV and III, respectively, but not from lower grade gliomas.
The most prevalent method of culturing glioblastoma cells, in traditional growth medium supplemented with 10% FBS, leads to considerable genomic and phenotypic divergence from the original tumors 4 . On the other hand, neurosphere cultures are a stable and long term source of cells presenting cancer stem cell phenotype 4 . The neurosphere method has become increasingly popular for the enrichment of CSC in long term cultures for orthotopic mouse xenograft models, despite not being successful for all high grade astrocytoma samples, which represents the main weakness of this method. Studies to understand how molecular characteristics of the parental tumors can affect neurosphere formation are underway. Exploration of practical alternative methods to culture high grade gliomas, followed by extensive validation are granted, given the momentous advantages of having patient specific GBM models, as we advance into an era of personalized medicine, fuelled by the accessibility of "omics" information and increased numbers of potential targeted therapies.
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